A 65-year-old patient with metastatic melanoma, who failed two immunotherapy strategies, received 2 mg/kg intravenously weekly BCT-100. The patient had no toxicities > grade 2 and achieved CR for over 30 months. The tumor lacked expression of ASS1 and OTC. The gene discussed is OTC; the disease is metastatic melanoma.